Immunotherapy shows promise in reducing recurrence rates for high-risk skin cancer, despite mixed results in recent clinical ...

Non-small cell lung cancer (NSCLC) develops in lung tissues, but when it's metastatic, it has spread to distant areas of the ...

Panelists discuss how the PODIUM-303 study demonstrated improved progression-free survival (9.3 vs 7.4 months) and response rates (56% vs 44%) when adding retifanlimab to carboplatin-paclitaxel in ...

Non-Small Cell Lung Cancer Market grows as immunotherapy approvals by Merck & Bristol-Myers reshape global treatment pathways. Anurag Tiwari Orion Market Research Pvt Ltd +91 91798 28694 email us here ...

Survival for non-small-cell lung cancer (NSCLC) remains unacceptably low, even in stage IA–IIA. Current guidelines recommend adjuvant treatment for patients considered to be at high risk in stages IB ...

Jain: Hi, thanks for having me. I'm Dr. Prantesh Jain, a thoracic oncologist at Roswell Park Cancer Center, and I'm excited to be here to share updates in lung cancer from ASCO this year. Sabari: ...

A phase 3 trial published in The Lancet found that combining Zepzelca (lurbinectedin) with Tecentriq (atezolizumab) as first-line maintenance therapy for extensive-stage small-cell lung cancer ...

Locally advanced (generally stage 3) head and neck squamous cell carcinoma is cancer that has grown outside its original location but has not yet spread to distant sites. It can be challenging to ...